Related Experiment Video
Updated: Jul 6, 2025
08:17
A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
Published on: August 15, 2019
14.5K
Non-classical Monocytes Enhance the Efficacy of Immune Checkpoint Inhibitors on Colon Cancer in a Syngeneic Mouse
Tsubasa Goshima1,2,3, Katsuaki Ieguchi1,4, Nobuyuki Onishi1,4
1Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.
Anticancer Research
|December 30, 2023
Summary
Non-classical monocytes (NCMs) boost the effectiveness of immune checkpoint inhibitors (ICIs) in colon cancer models. This combination therapy significantly improved tumor eradication and survival rates compared to ICIs alone.
Area of Science:
- Immunology
- Oncology
- Cancer Research
Background:
- Immune checkpoint inhibitors (ICIs) show limited response rates (10-30%) across few cancer types.
- Enhancing ICI efficacy is crucial for improving patient outcomes in various cancers.
Purpose of the Study:
- To investigate the potential of non-classical monocytes (NCMs) to augment ICI efficacy in colon cancer.
- To evaluate the combined therapeutic effect of NCMs and anti-PD-L1 antibodies in a preclinical colon cancer model.
Main Methods:
- Utilized the MC38 C57BL/6 mouse colon cancer model.
- Isolated and cultured non-classical monocytes (NCMs) from mouse bone marrow.
- Administered NCMs and anti-mouse PD-L1 antibody to tumor-bearing mice, monitoring tumor volume and survival.
Main Results:
- Combination therapy with NCMs and ICIs resulted in greater tumor eradication and complete response rates compared to ICIs alone.
- Administration of NCMs alone did not show any significant therapeutic effect.
- NCMs demonstrated a synergistic effect when used in conjunction with ICIs.
Conclusions:
- Non-classical monocytes (NCMs) significantly enhance the efficacy of immune checkpoint inhibitors (ICIs) in colon cancer.
- Further research is warranted to elucidate the underlying mechanisms and explore clinical applications of NCM-based immunotherapy.
